The early studies in mouse psoriasis models and clinical trials have simultaneously demonstrated that immune reagents targeting cytokines, for example, IL-17 antagonists or other cytokines upstream and downstream of the inflammatory response, could effectively reverse psoriasis [78]. Here, IL17A is linked to psoriasis.